News | December 04, 2006

SCAI Abstract Deadline Extended

The Society for Cardiac Angiography and Interventions (SCAI) has extended the abstract deadline for its 30th Annual Scientific Sessions in Orlando, May 9-12, 2007. The new deadline is December 22, 2006 at midnight (EST).

The top three abstracts will received awards, and the top 10 abstracts selected will be featured for oral presentantion. All accepted abstracts will be published in the May 2007 edition of SCAI's Journal, “Catheterization and Cardiovascular Interventions.”

Abstract categories are:
-Acute Coronary Syndromes and Myocardial Infarction
-Adult Congenital
-Atherectomy/Plaque Modification
-Angiogenesis, Myogenesis, Cell Therapy and Gene Therapy
-Carotid Revascularization
-Complex PCI
-Contrast agents
-CTO
-Drug-Eluting Stents
-Endovascular & Peripheral Interventions (Excluding Neurovascular Intervention)
-Imaging: CT & MR
-Intravascular Imaging/Physiology
-Left Main & Multi-Vessel Intervention
-Interventions for Myocardial Infarction
-Miscellaneous
-Neurovascular, Carotid & Stroke Intervention
-Non-Invasive Imaging
-Pediatric
-Pharmacotherapy
-PTCA
-Restenosis
-Stents
-Thrombectomy and Distal Protection Devices
-Valvular Interventions
-Vascular Access & Arterial Closure Devices
-Vulnerable Plaque
-Women's Healthcare

For more information or to submit an abstract, visit www.scai.org.

Related Content

Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
Overlay Init